Overview

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Status:
COMPLETED
Trial end date:
2025-05-08
Target enrollment:
Participant gender:
Summary
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Phase:
PHASE2
Details
Lead Sponsor:
Evommune, Inc.